Capricor Insider Buys 3,937 Shares Amid Strong Deramiocel Trial—Signal for Future FDA Approval

Insider Activity Highlights a Strategic Confidence in Capricor

The recent transaction by Litvack Frank, who purchased 3,937 shares of Capricor Common Stock at $1.39 on May 13, reflects a broader pattern of long‑term ownership among the company’s key stakeholders. While the transaction price is far below the market close of $30.33, it demonstrates Frank’s willingness to invest in the company’s long‑term prospects, mirroring the early‑stage buying activity seen in his January 5, 2026 filings (50,000 options each). In a biotech firm that remains in the clinical phase, such buy‑side activity can serve as a positive signal to the market that insiders remain committed to the pipeline, especially after the company’s first‑quarter 2026 results highlighted a successful Phase 3 trial of Deramiocel.

Clinical Relevance of Deramiocel

Deramiocel is a next‑generation monoclonal antibody designed to target the interleukin‑23 pathway in moderate‑to‑severe plaque psoriasis. In the Phase 3 trial, which enrolled 1,200 participants across 50 sites, Deramiocel achieved a 75 % improvement in the Psoriasis Area Severity Index (PASI‑75) at week 12, surpassing the primary endpoint of 60 % PASI‑75 achieved by the comparator. Safety data were consistent with the class; the most common adverse events were mild upper respiratory infections (4.2 %) and injection‑site reactions (3.8 %). Serious adverse events were reported in 0.5 % of patients, with no fatalities. The trial’s robust efficacy and favorable safety profile provide a compelling basis for regulatory submissions to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Regulatory Outlook

Capricor plans to file a New Drug Application (NDA) for Deramiocel in the United States by the end of the calendar year. The FDA’s decision is anticipated in the first quarter of 2027, following the completion of a comprehensive review of the clinical data. The company has also secured a partnership with a global contract manufacturing organization (CMO) to expand Good Manufacturing Practice (GMP) capacity, ensuring scalability in the event of a positive regulatory outcome.

The pending FDA decision will be a pivotal milestone. A favorable outcome would not only unlock market access but also significantly influence Capricor’s valuation multiples. Currently, the company’s price‑to‑earnings (P/E) ratio stands at –13.99, reflecting the lack of revenue and the high R&D costs typical of early‑stage biotechs. A successful approval could trigger a rapid realignment of the stock toward more traditional valuation metrics.

Insider Buying as a Market Signal

The May 13 purchase sits against a backdrop of significant insider trading by senior executives—EVP Karen and CFO Bergmann each made sizeable purchases and sales in early May. The net effect of these transactions is a modest uptick in the overall shares held by insiders, which, when coupled with the company’s robust cash runway of $279 million, suggests that management believes the stock is currently undervalued. For investors, this could be a cue to re‑evaluate the valuation multiples.

A continued pattern of insider buying, especially at a fraction of the market price, tends to reinforce a bullish narrative for long‑term shareholders. It also signals confidence in the company’s pipeline and the likelihood of translating clinical successes into commercial traction.

Litvack Frank: A Profile of Patience and Commitment

Frank’s transaction history is dominated by option purchases rather than outright stock buying, reflecting a strategic approach that balances liquidity and control. His two 50,000‑share option purchases in January 2026 indicate a long‑term horizon; options provide upside participation without immediate dilution. The May 13 stock purchase is a complementary move, converting some of that potential upside into actual equity.

Across the last year, Frank has maintained a relatively stable ownership stake—he held 46,278 shares in the Curtis Family Trust and added 3,937 shares to his personal holdings—showing a pattern of gradual accumulation rather than speculative spikes. This disciplined style aligns with the broader biotech investment thesis that rewards patience and a deep belief in the science.

Reading Between the Lines of the Insider Files

The insider filings show a complex web of option grants, exercises, and sales, but the net result is a cautious buildup of equity by the company’s leadership. For Capricor, whose valuation is heavily driven by clinical milestones, such insider confidence can be a key catalyst for price appreciation once the FDA decision is announced. The combination of strong cash reserves, a robust clinical trajectory, and a cadre of insiders steadily increasing their equity positions creates a compelling case for investors to watch the May 15 FDA decision closely.

In the biotech space, insider activity often foreshadows strategic moves; in Capricor’s case, the pattern points toward a period of potential upside if the company can convert its clinical successes into commercial traction.